Andrei P. Sommer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Andrei P. Sommer has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Horst-Dieter Försterling
Philipps University Marburg, Marburg, Germany
6 shared publicationsAdam R. Mester
National Laser Centre, Peterfy Sandor Teaching Hospital, 1076 Budapest, Hungary
2 shared publications- Dan Zhu
Ministry of Education Key Laboratory of NSLSCS, School of Computer and Electronic Information, Nanjing Normal University, Nanjing, China
2 shared publications - Arnaud Caron
KoreaTech – Korea University of Technology and Education
1 shared publication Attila E. Pavláth
Past President American Chemical Society, Western Regional Research Center, Albany, CA, USA
1 shared publicationAttila Pavláth
Western Regional Research Center, Albany, CA, USA
1 shared publication
Latest Publications
- Open Access
- 26 July 2022
- Published by Andover House Inc in Precision Nanomedicine
- Vol. 5 (3) , 897-903
Long COVID, Music, BBB, and Nanomedicines
At the beginning of the first COVID-19 wave, it was believed that the life of the patients who had safely survived pulmonary complications caused by SARS-CoV-2 would soon return to normal. Today, we know that this is not for all patients the case. Unfortunately, for many patients, COVID-19 changed into long COVID – not a life-threatening condition such as the short period of the infection with the coronavirus but with the potential to considerably reduce the quality of life. Notably, long COVID manifests itself in major pathological alteration in the brain, besides other organs. It is unclear whether the alterations in the brain are reversible. Alterations can include but are not limited to cognitive impairment and substantial reduction of grey matter. These clinical findings represent an urgent challenge for the design of nanomedicines targeting the brain and the mode of their application. The challenge comprises a third aspect, which is of physical nature and is the key to a revolution in nanomedicine: the blood-brain barrier (BBB). Even if nanomedicine is effective in vitro, it remains therapeutically useless if it cannot cross the BBB, safeguarding that neither pathogens nor nanoparticles enter the best-protected organ in our body. Here, we present a theoretical model and discuss experimental results, which coherently indicate that it can transiently open the BBB by its mechanical excitation and/or via chemical modification induced by music.
- 26 July 2022
- Published by Andover House Inc in Precision Nanomedicine
- Vol. 5 (3) , 897-903
Open AccessLong COVID, Music, BBB, and Nanomedicines
At the beginning of the first COVID-19 wave, it was believed that the life of the patients who had safely survived pulmonary complications caused by SARS-CoV-2 would soon return to normal. Today, we know that this is not for all patients the case. Unfortunately, for many patients, COVID-19 changed into long COVID – not a life-threatening condition such as the short period of the infection with the coronavirus but with the potential to considerably reduce the quality of life. Notably, long COVID manifests itself in major pathological alteration in the brain, besides other organs. It is unclear whether the alterations in the brain are reversible. Alterations can include but are not limited to cognitive impairment and substantial reduction of grey matter. These clinical findings represent an urgent challenge for the design of nanomedicines targeting the brain and the mode of their application. The challenge comprises a third aspect, which is of physical nature and is the key to a revolution in nanomedicine: the blood-brain barrier (BBB). Even if nanomedicine is effective in vitro, it remains therapeutically useless if it cannot cross the BBB, safeguarding that neither pathogens nor nanoparticles enter the best-protected organ in our body. Here, we present a theoretical model and discuss experimental results, which coherently indicate that it can transiently open the BBB by its mechanical excitation and/or via chemical modification induced by music.
- Open Access
- 25 June 2021
- Published by Andover House Inc in Precision Nanomedicine
- Vol. 4 (2) , 795-800
Pulmonary and intranasal delivery of thymoquinone-loaded nanoparticles for Mucormycosis & Covid-19
India is currently reporting a massive increase of mucormycosis infection among Covid-19 patients. The opportunistic black fungus infection affects the lungs and the brain. Depending on the infected organs, morbidity and mortality rates are between 50% and 100%. To save patients’ life, it is frequently necessary to remove jaws and eyes. The drug of the first choice for the treatment of mucormycosis in the subcontinent is amphotericin B. There are two problems with amphotericin B: First, it is currently not available in many pharmacies in India, and second, its effect is restricted by its limited passage across the blood-brain barrier. Recently, it was shown that thymol is highly effective against Rhizopus oryzea, the fungus causing 70% of mucormycosis. In contrast to amphotericin B, which in the case of mucormycosis is administered intravenously, thymol can reach the lungs via inhalation and the brain via the nose-to-brain route. Importantly, thymoquinone (TQ) has all the relevant biological properties of thymol and has already been successfully used to treat Covid-19, as demonstrated in clinical studies. In addition to the action spectrum of thymol, TQ can act as a reactive oxygen species and oxidize pathogens upon contact, thereby recommending itself for both treatment of Covid-19 and infections with the black fungus. For maximum efficacy, comprising biodistribution, bioavailability, and drug functionality, we describe innovative strategies based on nanomedicines for targeted delivery of TQ to the lungs and intranasal delivery to the brain, bypassing the blood-brain barrier. After these promising strategies as the next step, a clinical study for proof of concept should be initiated.
- 25 June 2021
- Published by Andover House Inc in Precision Nanomedicine
- Vol. 4 (2) , 795-800
Open AccessPulmonary and intranasal delivery of thymoquinone-loaded nanoparticles for Mucormycosis & Covid-19
India is currently reporting a massive increase of mucormycosis infection among Covid-19 patients. The opportunistic black fungus infection affects the lungs and the brain. Depending on the infected organs, morbidity and mortality rates are between 50% and 100%. To save patients’ life, it is frequently necessary to remove jaws and eyes. The drug of the first choice for the treatment of mucormycosis in the subcontinent is amphotericin B. There are two problems with amphotericin B: First, it is currently not available in many pharmacies in India, and second, its effect is restricted by its limited passage across the blood-brain barrier. Recently, it was shown that thymol is highly effective against Rhizopus oryzea, the fungus causing 70% of mucormycosis. In contrast to amphotericin B, which in the case of mucormycosis is administered intravenously, thymol can reach the lungs via inhalation and the brain via the nose-to-brain route. Importantly, thymoquinone (TQ) has all the relevant biological properties of thymol and has already been successfully used to treat Covid-19, as demonstrated in clinical studies. In addition to the action spectrum of thymol, TQ can act as a reactive oxygen species and oxidize pathogens upon contact, thereby recommending itself for both treatment of Covid-19 and infections with the black fungus. For maximum efficacy, comprising biodistribution, bioavailability, and drug functionality, we describe innovative strategies based on nanomedicines for targeted delivery of TQ to the lungs and intranasal delivery to the brain, bypassing the blood-brain barrier. After these promising strategies as the next step, a clinical study for proof of concept should be initiated.
- Open Access
- 10 April 2021
- Published by Andover House Inc in Precision Nanomedicine
Mitochondrial photo field-effect transistor: quantum tunneling & photosensitivity – model explaining the brain death dogma challenge
Low level light therapy (LLLT) uses moderate light intensities delivered by red to near infrared (R-NIR) lasers or light emitting diodes (LED) operating in the 1 - 4 J/cm2 dose window, effective in vitro and in vivo. Pulsed LLLT forces cells and tissues to uptake nanoparticles. During a severe infection with all the lead symptoms of Covid-19, LLLT has been used to treat a painful frontal sinusitis (8). Could LLLT be extended to treat further manifestation of Covid-19? The author addresses this question in his poster presentation at the 2020 CLINAM meeting.
- 10 April 2021
- Published by Andover House Inc in Precision Nanomedicine
Open AccessMitochondrial photo field-effect transistor: quantum tunneling & photosensitivity – model explaining the brain death dogma challenge
Low level light therapy (LLLT) uses moderate light intensities delivered by red to near infrared (R-NIR) lasers or light emitting diodes (LED) operating in the 1 - 4 J/cm2 dose window, effective in vitro and in vivo. Pulsed LLLT forces cells and tissues to uptake nanoparticles. During a severe infection with all the lead symptoms of Covid-19, LLLT has been used to treat a painful frontal sinusitis (8). Could LLLT be extended to treat further manifestation of Covid-19? The author addresses this question in his poster presentation at the 2020 CLINAM meeting.
- Open Access
- 30 October 2020
- Published by Georg Thieme Verlag KG in Drug Research
- Vol. 71 (01) , 4-9
Tutankhamun’s Antimalarial Drug for Covid-19
Drug repositioning is a strategy that identifies new uses of approved drugs to treat conditions different from their original purpose. Current efforts to treat Covid-19 are based on this strategy. The first drugs used in patients infected with SARS-CoV-2 were antimalarial drugs. It is their mechanism of action, i. e., rise in endosomal pH, which recommends them against the new coronavirus. Disregarding their side effects, the study of their antiviral activity provides valuable hints for the choice and design of drugs against SARS-CoV-2. One prominent drug candidate is thymoquinone, an antimalarial substance contained in Nigella sativa – most likely one of the first antimalarial drugs in human history. Since the outbreak of the pandemic, the number of articles relating thymoquinone to Covid-19 continuously increases. Here, we use it as an exemplary model drug, compare its antiviral mechanism with that of conventional antimalarial drugs and establish an irreducible parametric scheme for the identification of drugs with a potential in Covid-19.Translation into the laboratory is simple. Starting with the discovery of Nigella sativa seeds in the tomb of Pharaoh Tutankhamun, we establish a physicochemical model for the interaction of thymoquinone with both coronavirus and cells. Exploiting the predictive capability of the model, we provide a generalizable scheme for the systematic choice and design of drugs for Covid-19. An unexpected offshoot of our research is that Tutankhamun could not have died of malaria, a finding contrary to the mainstream theory. Received: 01 September 2020 Accepted: 28 September 2020 Publication Date: 30 October 2020 (online) © 2020. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 30 October 2020
- Published by Georg Thieme Verlag KG in Drug Research
- Vol. 71 (01) , 4-9
Open AccessTutankhamun’s Antimalarial Drug for Covid-19
Drug repositioning is a strategy that identifies new uses of approved drugs to treat conditions different from their original purpose. Current efforts to treat Covid-19 are based on this strategy. The first drugs used in patients infected with SARS-CoV-2 were antimalarial drugs. It is their mechanism of action, i. e., rise in endosomal pH, which recommends them against the new coronavirus. Disregarding their side effects, the study of their antiviral activity provides valuable hints for the choice and design of drugs against SARS-CoV-2. One prominent drug candidate is thymoquinone, an antimalarial substance contained in Nigella sativa – most likely one of the first antimalarial drugs in human history. Since the outbreak of the pandemic, the number of articles relating thymoquinone to Covid-19 continuously increases. Here, we use it as an exemplary model drug, compare its antiviral mechanism with that of conventional antimalarial drugs and establish an irreducible parametric scheme for the identification of drugs with a potential in Covid-19.Translation into the laboratory is simple. Starting with the discovery of Nigella sativa seeds in the tomb of Pharaoh Tutankhamun, we establish a physicochemical model for the interaction of thymoquinone with both coronavirus and cells. Exploiting the predictive capability of the model, we provide a generalizable scheme for the systematic choice and design of drugs for Covid-19. An unexpected offshoot of our research is that Tutankhamun could not have died of malaria, a finding contrary to the mainstream theory. Received: 01 September 2020 Accepted: 28 September 2020 Publication Date: 30 October 2020 (online) © 2020. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 20 May 2020
- Published by Andover House Inc in Precision Nanomedicine
- p. 541-548
Thymoquinone: shield and sword against SARS-CoV-2
Since its emergence, the epidemic scale of the new coronavirus (SARS-CoV-2) has increased at an extraordinary rate. Governments, medical personnel, researchers and companies work at the limit of their capabilities, in attempts to combat the virus. Companies are giving up current projects and change their activities to help fighting the virus. In this difficult time, every piece of useful information is valuable. Here, we bring to the attention of the scientific and medical community thymoquinone (TQ), a substance unknown to experts in western countries, which holds the promise to help treating people infected with this novel virus: (1) by inhibiting its proliferation, (2) by killing it, (3) by killing the bacteria associated with pneumonia, (4) by its anti-inflammatory and (5) immunomodulatory effect – perhaps acting synergistically, or even as a prophylactic remedy to prevent SARS-CoV-2 infection. However, due to the volatility of TQ, bioavailability in infected organs, specifically the lungs, is low. This is where nanomedicine is challenged. Nanocarriers targeting the lungs exist and TQ has already been successfully used in nanomedicines targeting different organs, except the lungs. Thus, there is not a long way to go. It was an anecdotal case report that stimulated the investigation of the therapeutic effect of TQ and the derivation of a mechanism for its dual antiviral action, applicable to Covid-19. Furthermore, by exploiting the material published on the antiviral effect of TQ, we compared the antiviral mechanism of TQ with that of chloroquine (CQ) and hydroxychloroquine (HCQ). Our analysis indicates that the antiviral action of TQ is similar and most likely superior to that of CQ and HCQ, however, apparently without the adverse effects reported for CQ and HCQ. The broad antiviral spectrum and the mechanism by which TQ presumably neutralizes the new virus, justifies the hypothesis that TQ is effective to treat Covid-19. [READ ARTICLE](https://precisionnanomedicine.com/article/12984)
- 20 May 2020
- Published by Andover House Inc in Precision Nanomedicine
- p. 541-548
Open AccessThymoquinone: shield and sword against SARS-CoV-2
Since its emergence, the epidemic scale of the new coronavirus (SARS-CoV-2) has increased at an extraordinary rate. Governments, medical personnel, researchers and companies work at the limit of their capabilities, in attempts to combat the virus. Companies are giving up current projects and change their activities to help fighting the virus. In this difficult time, every piece of useful information is valuable. Here, we bring to the attention of the scientific and medical community thymoquinone (TQ), a substance unknown to experts in western countries, which holds the promise to help treating people infected with this novel virus: (1) by inhibiting its proliferation, (2) by killing it, (3) by killing the bacteria associated with pneumonia, (4) by its anti-inflammatory and (5) immunomodulatory effect – perhaps acting synergistically, or even as a prophylactic remedy to prevent SARS-CoV-2 infection. However, due to the volatility of TQ, bioavailability in infected organs, specifically the lungs, is low. This is where nanomedicine is challenged. Nanocarriers targeting the lungs exist and TQ has already been successfully used in nanomedicines targeting different organs, except the lungs. Thus, there is not a long way to go. It was an anecdotal case report that stimulated the investigation of the therapeutic effect of TQ and the derivation of a mechanism for its dual antiviral action, applicable to Covid-19. Furthermore, by exploiting the material published on the antiviral effect of TQ, we compared the antiviral mechanism of TQ with that of chloroquine (CQ) and hydroxychloroquine (HCQ). Our analysis indicates that the antiviral action of TQ is similar and most likely superior to that of CQ and HCQ, however, apparently without the adverse effects reported for CQ and HCQ. The broad antiviral spectrum and the mechanism by which TQ presumably neutralizes the new virus, justifies the hypothesis that TQ is effective to treat Covid-19. [READ ARTICLE](https://precisionnanomedicine.com/article/12984)
- Open Access
- 1 April 2020
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 8 (7) , 440
Quantum biology in low level light therapy: death of a dogma
Background: It is shown that despite exponential increase in the number of clinically exciting results in low level light therapy (LLLT), scientific progress in the field is retarded by a wrong fundamental model employed to explain the photon-cell interaction as well as by an inadequate terminology. This is reflected by a methodological stagnation in LLLT, persisting since 1985. The choice of the topics is, by necessity, somewhat arbitrary. Obviously, we are writing more about the fields we know more about. In some cases, there are obvious objective reasons for the choice. Progress in LLLT is currently realized by a trial and error process, as opposed to a systematic approach based on a valid photon-cell interaction model. Methods: The strategy to overcome the current problem consists in a comprehensive analysis of the theoretical foundation of LLLT, and if necessary, by introducing new interaction models and checking their validity on the basis of the two pillars of scientific advance (I) agreement with experiment and (II) predictive capability. The list of references used in this work, does contain a representative part of what has been done in the photon-cell interaction theory in recent years, considered as ascertained by the scientific community. Results: Despite the immense literature on the involvement of cytochrome c oxidase (COX) in LLLT, the assumption that COX is the main mitochondrial photoacceptor for R-NIR photons no longer can be counted as part of the theoretical framework proper, at least not after we have addressed the misleading points in the literature. Here, we report the discovery of a coupled system in mitochondria whose working principle corresponds to that of field-effect transistor (FET). The functional interplay of cytochrome c (emitter) and COX (drain) with a nanoscopic interfacial water layer (gate) between the two enzymes forms a biological FET in which the gate is controlled by R-NIR photons. By reducing the viscosity of the nanoscopic interfacial water layers within and around the mitochondrial rotary motor in oxidatively stressed cells R-NIR light promotes the synthesis of extra adenosine triphosphate (ATP). Conclusions: Based on the results of our own work and a review of the published literature, we present the effect of R-NIR photons on nanoscopic interfacial water layers in mitochondria and cells as a novel understanding of the biomedical effects R-NIR light. The novel paradigm is in radical contrast to the theory that COX is the main absorber for R-NIR photons and responsible for the increase in ATP synthesis, a dogma propagated for more than 20 years.
- 1 April 2020
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 8 (7) , 440
Open AccessQuantum biology in low level light therapy: death of a dogma
Background: It is shown that despite exponential increase in the number of clinically exciting results in low level light therapy (LLLT), scientific progress in the field is retarded by a wrong fundamental model employed to explain the photon-cell interaction as well as by an inadequate terminology. This is reflected by a methodological stagnation in LLLT, persisting since 1985. The choice of the topics is, by necessity, somewhat arbitrary. Obviously, we are writing more about the fields we know more about. In some cases, there are obvious objective reasons for the choice. Progress in LLLT is currently realized by a trial and error process, as opposed to a systematic approach based on a valid photon-cell interaction model. Methods: The strategy to overcome the current problem consists in a comprehensive analysis of the theoretical foundation of LLLT, and if necessary, by introducing new interaction models and checking their validity on the basis of the two pillars of scientific advance (I) agreement with experiment and (II) predictive capability. The list of references used in this work, does contain a representative part of what has been done in the photon-cell interaction theory in recent years, considered as ascertained by the scientific community. Results: Despite the immense literature on the involvement of cytochrome c oxidase (COX) in LLLT, the assumption that COX is the main mitochondrial photoacceptor for R-NIR photons no longer can be counted as part of the theoretical framework proper, at least not after we have addressed the misleading points in the literature. Here, we report the discovery of a coupled system in mitochondria whose working principle corresponds to that of field-effect transistor (FET). The functional interplay of cytochrome c (emitter) and COX (drain) with a nanoscopic interfacial water layer (gate) between the two enzymes forms a biological FET in which the gate is controlled by R-NIR photons. By reducing the viscosity of the nanoscopic interfacial water layers within and around the mitochondrial rotary motor in oxidatively stressed cells R-NIR light promotes the synthesis of extra adenosine triphosphate (ATP). Conclusions: Based on the results of our own work and a review of the published literature, we present the effect of R-NIR photons on nanoscopic interfacial water layers in mitochondria and cells as a novel understanding of the biomedical effects R-NIR light. The novel paradigm is in radical contrast to the theory that COX is the main absorber for R-NIR photons and responsible for the increase in ATP synthesis, a dogma propagated for more than 20 years.
- Open Access
- 1 March 2020
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 8 (5) , 161
Mitochondrial solar sensitivity: evolutionary and biomedical implications
Mitochondrial solar sensitivity: evolutionary and biomedical implications
- 1 March 2020
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 8 (5) , 161
Open AccessMitochondrial solar sensitivity: evolutionary and biomedical implications
Mitochondrial solar sensitivity: evolutionary and biomedical implications
- 1 June 2019
- Published by SAGE Publications in Photobiomodulation, Photomedicine, and Laser Surgery
- Vol. 37 (6) , 336-341
Revisiting the Photon/Cell Interaction Mechanism in Low-Level Light Therapy
Objective: Several reports claim that the enzyme cytochrome c oxidase (CCO) is the primary absorber for red-to-near-infrared (R-NIR) light in cells and causal for mitochondrial adenosine triphosphate (ATP) upregulation, and that pulsed R-NIR light has frequent therapeutic effects, which are superior to those of the continuous wave (CW) mode used in low-level light therapy (LLLT). Background data: Convincing evidence that the absorption of R-NIR photons by CCO is involved in mitochondrial ATP upregulations as well as a coherent explanation for the superiority of the pulsed irradiation mode is presently lacking in the literature. Methods: A comprehensive literature search and rigorous analysis of the data published on the idea that CCO is the primary absorber for R-NIR light, and of the claim that the effectivity of the pulsed irradiation mode can be derived from the absorption of R-NIR photons by CCO, reveal a number of severe inconsistencies. Results: A systematical analysis covering both the theory that CCO is the primary acceptor for R-NIR light and of its use to interpret differences between the biological effect of pulsed light and CW casts doubt on the general validity of the CCO-based hypothesis. Instead, we are offered a simple and conflict-free model accounting for both ATP upregulation and superiority of the pulsed mode in LLLT, which is in agreement with the results of recent laboratory experiments. Conclusions: CCO is not the primary acceptor for R-NIR light.
- 1 June 2019
- Published by SAGE Publications in Photobiomodulation, Photomedicine, and Laser Surgery
- Vol. 37 (6) , 336-341
Revisiting the Photon/Cell Interaction Mechanism in Low-Level Light Therapy
Objective: Several reports claim that the enzyme cytochrome c oxidase (CCO) is the primary absorber for red-to-near-infrared (R-NIR) light in cells and causal for mitochondrial adenosine triphosphate (ATP) upregulation, and that pulsed R-NIR light has frequent therapeutic effects, which are superior to those of the continuous wave (CW) mode used in low-level light therapy (LLLT). Background data: Convincing evidence that the absorption of R-NIR photons by CCO is involved in mitochondrial ATP upregulations as well as a coherent explanation for the superiority of the pulsed irradiation mode is presently lacking in the literature. Methods: A comprehensive literature search and rigorous analysis of the data published on the idea that CCO is the primary absorber for R-NIR light, and of the claim that the effectivity of the pulsed irradiation mode can be derived from the absorption of R-NIR photons by CCO, reveal a number of severe inconsistencies. Results: A systematical analysis covering both the theory that CCO is the primary acceptor for R-NIR light and of its use to interpret differences between the biological effect of pulsed light and CW casts doubt on the general validity of the CCO-based hypothesis. Instead, we are offered a simple and conflict-free model accounting for both ATP upregulation and superiority of the pulsed mode in LLLT, which is in agreement with the results of recent laboratory experiments. Conclusions: CCO is not the primary acceptor for R-NIR light.
- Open Access
- 1 March 2019
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 7 (S1) , S13
Mitochondrial cytochrome c oxidase is not the primary acceptor for near infrared light—it is mitochondrial bound water: the principles of low-level light therapy
Mitochondrial cytochrome c oxidase is not the primary acceptor for near infrared light—it is mitochondrial bound water: the principles of low-level light therapy
- 1 March 2019
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 7 (S1) , S13
Open AccessMitochondrial cytochrome c oxidase is not the primary acceptor for near infrared light—it is mitochondrial bound water: the principles of low-level light therapy
Mitochondrial cytochrome c oxidase is not the primary acceptor for near infrared light—it is mitochondrial bound water: the principles of low-level light therapy
- 1 February 2014
- Published by SAGE Publications in Photomedicine and Laser Surgery
- Vol. 32 (2) , 59-60
Light Pumping Energy Into Blood Mitochondria: A New Trend Against Depression?
- 1 February 2014
- Published by SAGE Publications in Photomedicine and Laser Surgery
- Vol. 32 (2) , 59-60
Light Pumping Energy Into Blood Mitochondria: A New Trend Against Depression?